Locked Nucleic Acids (LNAs) are RNA analogs that provide more stable Watson-Crick base-pairing. LNA ribonucleotides can be added into RNA and DNA oligonucleotides to increase the affinity of these oligonucleotides for their complementary sequences. In addition, these LNA present oligonucleotides have extraordinary single-nucleotide discrimination as well as enhanced stability,…
In episode #91 of The Weekly Bioanalysis, John and Dom return to a two-person format to tackle the “gray areas” of bioanalysis, focusing on drug discovery, biomarkers, tissues, and emerging technologies. They discuss how traditional PK assay validation is highly standardized, but areas like early-stage discovery, biomarker qualification, and…
Screening experiments have become the backbone of modern drug discovery and biological research, enabling the evaluation of thousands of compounds simultaneously. However, screening success hinges on two critical factors: (1) selecting appropriate cellular models and (2) designing robust experimental frameworks. Poor choices can lead to irreproducible results, failed clinical…
In biomarker-driven drug development, selecting the right assay format is critical for generating reliable data that informs scientific and clinical decisions. Whether quantifying proteins, immune cell subsets, or complex molecular signatures, the choice between off-the-shelf and customized assays has direct implications for timelines, costs, and how well the assay…
In this episode, the hosts introduce Karla Moncada, who shares her professional journey from Flowcore management to her current role at KCAS Bio, and unveils her new KCAS Bio video series, Karla’s Corner, aimed at fostering year-round conversations within the flow cytometry community. Karla emphasizes the value of personal…
Join KCAS Bio at the 18th EBF Open Symposium, taking place in Barcelona, Spain, on November 18-20. This event will bring together scientists from around the globe to discuss a broad array of bioanalytical topics. With the theme “Tuning in to Tomorrow,” The EBF Open Symposium will include…
KCAS Bio will participate in the AMP 2025 Annual Meeting & Expo, taking place November 11-15 in Boston, MA. The AMP 2025 Annual Meeting brings together industry leaders and experts focused on advancing molecular diagnostics and precision medicine. The event covers the latest innovations in biomarker discovery, genomic…
KCAS Bio will be attending the NCCG Annual Meeting 2025, taking place in San Francisco on September 22. This gathering, hosted by NorCal Cytometry Group, unites professionals across the scientific, regulatory, and biotech communities who are interested in the advancements in the field of flow cytometry. The annual…
KCAS Bio will be attending MetroFlow 2025 Annual Meeting, taking place October 23 in New York, NY. The MetroFlow 2025 Annual Meeting brings together a dedicated community of flow cytometry professionals, including core facility directors, technical experts, researchers, and service providers. As such, this gathering provides a collaborative…
KCAS Bio will be participating in Nordic Life Science Days (NLS) Days 2025, taking place October 13-14 in Gothenburg, Sweden. The conference focuses on early-stage drug development, partnerships, and innovation within the life sciences sector. Hosted by SwedenBIO, NLSDays brings together top scientists and business developers from across…
KCAS Bio will be participating in the Immunogenicity & Bioassay Summit 2025, taking place October 7-10 in Alexandria, VA. This annual summit, hosted by the Cambridge Healthtech Institute, brings together leaders in immunogenicity assessment, bioassay development, and translational science to explore emerging strategies in drug development. With focused…
In the ever-evolving landscape of drug development, biomarkers have emerged as critical tools for the mechanism of action, early proof of mechanism, safety, predictive, efficacy, and monitoring treatment response. As the field advances, two major classes of biomarkers have come to the forefront: soluble biomarkers and cellular biomarkers.